Primary outcome: Primary: Change in Baseline Smoking Abstinence at 6 and 10 Weeks After Genotyping Results — 1; 0; 7; 11 Participants
Study Design & Population
Study type
Interventional
Phase
N/A
Interventions
Receipt of Genetic Results (Behavioral); No results given (Behavioral)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of Nebraska
Primary completion
Aug 2013
Outcome Measures
Outcome
Result
p-value
PRIMARY Change in Baseline Smoking Abstinence at 6 and 10 Weeks After Genotyping Results
1; 0; 7; 11
—
SECONDARY Change in Baseline Use of Pharmacotherapy at 6 and 10 Weeks After Genotyping Results
2; 2; 6; 9
—
Summary
Innovative strategies to reduce adult smoking prevalence include using genetic information to motivate cessation and, ultimately, to tailor cessation pharmacotherapy. Success of these interventions depends, in part, on smokers' interest and participation in genetic testing related to cessation and their understanding and use of the results (i.e., their genetic literacy). The recent availability of genetic risk testing for a nicotinic acetylcholine receptor gene (CHRNA3) variant (rs105173) associated with nicotine dependence makes it highly feasible to investigate smokers' interest in and use of genetic information about nicotine dependence. Therefore, the primary purpose of this study is to determine the impact of an intervention that provides smokers with an educational session about genetic contributions to smoking and nicotine dependence plus their genotype results for rs1051730 on smoking cessation outcomes compared to those who receive only the educational session. Secondary purposes are to determine: (a) the impact of genetic education and knowing personal genotype results on genetic literacy outcomes and (b) the feasibility of recruitment and retention methods in a study addressing genotyping for nicotine dependence. Primary outcomes are cessation-related behaviors and cognitions indicating abstinence. Secondary outcomes are cognitions and emotions indicating genetic literacy. Knowledge gained from this study has the potential for clinical translation so that as genotyping becomes part of smoking cessation, health-care providers can understand and address factors influencing smokers' adaptation to genetically-informed cessation treatment. The study will use a longitudinal, repeated measures design (experimental, control; N=90; 45/group). All participants will receive a 90-minute educational session about genetic contributions for smoking and nicotine dependence and will donate a buccal swab sample for genotyping. The investigators will then randomize participants to two groups: those who receive genotyping results in a genetic counseling session (experimental) and those who do not (control). Follow-up data will be collected from both groups at baseline and weeks 2, 6, 10 after the experimental group receives genotyping results, with a brief follow-up and study termination occurring at week 12. Control group participants will be offered their genotyping results at the end of the study.
Eligibility Criteria
Inclusion Criteria
>19 years of age;
smoking>= 10 cigarettes/day;
intention to quit smoking at some time in the future;
able to understand, speak, and write in English, and
physically and mentally able to participate.
The investigators are excluding participants who do not understand, speak or write in English at this time because: (1) the consent document, the educational genetics presentation, and data collection forms are currently written in English only and (2)the resources to make the educational presentation and data collection documents culturally-specific for other cultures are not available. In making the study relevant for non-English speaking participants, it is not only a literal translation the presentation and documents into another language that is needed, but the ideas of health and heredity from the culture related to the language also need to be taken into account when presenting the study and the study materials in another language.
Exclusion Criteria
current treatment for a mental disorder with psychotic symptoms;
diagnosis of cancer (other than basal or squamous cell skin cancer) or other life-threatening illness;
pregnant, or
currently enrolled in another smoking research study.
Data sourced from ClinicalTrials.gov (NCT01780038). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.